Tevogen advances talks on strategic acquisitions, including CRO deal under review
PUBT · 05/28 16:30
Share
Listen to the news
- Tevogen Bio Holdings is pursuing strategic acquisitions, including evaluation of a contract research organization, targeting about $100 million in combined annual revenue.
- The deals are intended to add a healthcare services arm alongside Tevogen Bio and Tevogen.AI as the group pushes toward financial self-sufficiency.
- Any transactions remain subject to due diligence, definitive agreements, required approvals, and customary closing conditions.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tevogen Bio Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605281230PRIMZONEFULLFEED9728330) on May 28, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved